TR200000006T2 - Yeni formülasyon. - Google Patents

Yeni formülasyon.

Info

Publication number
TR200000006T2
TR200000006T2 TR2000/00006T TR200000006T TR200000006T2 TR 200000006 T2 TR200000006 T2 TR 200000006T2 TR 2000/00006 T TR2000/00006 T TR 2000/00006T TR 200000006 T TR200000006 T TR 200000006T TR 200000006 T2 TR200000006 T2 TR 200000006T2
Authority
TR
Turkey
Prior art keywords
new formulation
freeze drying
nucleotide analog
glass forming
pharmacological composition
Prior art date
Application number
TR2000/00006T
Other languages
English (en)
Turkish (tr)
Inventor
Broadhead Joanne
Original Assignee
Astra Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200000006(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Pharmaceuticals Ltd. filed Critical Astra Pharmaceuticals Ltd.
Publication of TR200000006T2 publication Critical patent/TR200000006T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TR2000/00006T 1997-07-11 1998-06-29 Yeni formülasyon. TR200000006T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Publications (1)

Publication Number Publication Date
TR200000006T2 true TR200000006T2 (tr) 2000-07-21

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00006T TR200000006T2 (tr) 1997-07-11 1998-06-29 Yeni formülasyon.

Country Status (35)

Country Link
US (1) US6130208A (enExample)
EP (1) EP1000079B1 (enExample)
JP (1) JP4950380B2 (enExample)
KR (1) KR100786654B1 (enExample)
CN (2) CN1864696A (enExample)
AR (1) AR013157A1 (enExample)
AT (1) ATE340801T1 (enExample)
AU (1) AU8362598A (enExample)
BR (1) BR9810703A (enExample)
CA (1) CA2295628C (enExample)
CY (1) CY1105805T1 (enExample)
CZ (1) CZ298110B6 (enExample)
DE (1) DE69836023T2 (enExample)
DK (1) DK1000079T3 (enExample)
EE (1) EE04119B1 (enExample)
ES (1) ES2273425T3 (enExample)
HU (1) HU226489B1 (enExample)
ID (1) ID24716A (enExample)
IL (2) IL133868A0 (enExample)
IS (1) IS2439B (enExample)
MY (1) MY116421A (enExample)
NO (1) NO329918B1 (enExample)
NZ (1) NZ502073A (enExample)
PL (1) PL192768B1 (enExample)
PT (1) PT1000079E (enExample)
RU (1) RU2216330C2 (enExample)
SA (1) SA98190328B1 (enExample)
SE (1) SE9702680D0 (enExample)
SI (1) SI1000079T1 (enExample)
SK (1) SK285766B6 (enExample)
TR (1) TR200000006T2 (enExample)
TW (1) TW585764B (enExample)
UA (1) UA65576C2 (enExample)
WO (1) WO1999002542A1 (enExample)
ZA (1) ZA985669B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879567B2 (en) * 2004-10-05 2011-02-01 Asahi Kasei Pharma Corporation Method for stabilizing coenzyme and composition therefor
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2011024933A1 (ja) 2009-08-28 2011-03-03 第一三共株式会社 ３－（ビアリールオキシ）プロピオン酸誘導体
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
FI2648701T3 (fi) * 2010-12-10 2023-06-12 Sigmapharm Laboratories Llc Hyvin stabiileja adefovirdipivoksiilin koostumuksia
EP2672975B1 (en) 2011-02-09 2016-04-20 The Medicines Company Methods for treating pulmonary hypertension
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
PL2964233T3 (pl) 2013-03-09 2022-04-25 Chiesi Farmaceutici S.P.A. Sposoby leczenia, zmniejszania częstości występowania i(lub) profilaktyki zdarzeń niedokrwiennych
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
CN115990138A (zh) 2015-01-14 2023-04-21 奇斯药制品公司 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法
MA49452A (fr) 2017-06-23 2021-05-05 Chiesi Farm Spa Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (enExample) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
AU3095092A (en) * 1991-12-09 1993-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
KR100315612B1 (ko) * 1993-02-10 2002-06-20 추후제출 N-알킬-2-치환아데노신트리포스페이트동족체
ZA949715B (en) * 1993-12-14 1996-06-06 Lilly Co Eli Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
WO1996040265A1 (en) * 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Prod New pharmaceutical formulation

Also Published As

Publication number Publication date
CY1105805T1 (el) 2011-02-02
KR100786654B1 (ko) 2007-12-21
DE69836023T2 (de) 2007-04-12
SK285766B6 (sk) 2007-07-06
PT1000079E (pt) 2006-12-29
IL133868A0 (en) 2001-04-30
ID24716A (id) 2000-08-03
NO20000123D0 (no) 2000-01-10
SK183699A3 (en) 2000-07-11
HK1026429A1 (en) 2000-12-15
EP1000079A1 (en) 2000-05-17
SI1000079T1 (sl) 2007-08-31
IS2439B (is) 2008-11-15
IL133868A (en) 2010-05-17
NO20000123L (no) 2000-03-03
EE200000022A (et) 2000-10-16
WO1999002542A1 (en) 1999-01-21
UA65576C2 (uk) 2004-04-15
PL192768B1 (pl) 2006-12-29
EP1000079B1 (en) 2006-09-27
EE04119B1 (et) 2003-08-15
CN1263533A (zh) 2000-08-16
CZ200083A3 (cs) 2000-06-14
NO329918B1 (no) 2011-01-24
SE9702680D0 (sv) 1997-07-11
BR9810703A (pt) 2000-08-08
HU226489B1 (en) 2009-03-02
CA2295628C (en) 2008-07-29
TW585764B (en) 2004-05-01
CN1864696A (zh) 2006-11-22
JP2001509512A (ja) 2001-07-24
HUP0002622A3 (en) 2002-04-29
SA98190328B1 (ar) 2006-08-15
NZ502073A (en) 2001-09-28
US6130208A (en) 2000-10-10
AU8362598A (en) 1999-02-08
DK1000079T3 (da) 2006-11-20
CA2295628A1 (en) 1999-01-21
ZA985669B (en) 1999-01-11
MY116421A (en) 2004-01-31
RU2216330C2 (ru) 2003-11-20
HUP0002622A2 (hu) 2001-05-28
JP4950380B2 (ja) 2012-06-13
KR20010021647A (ko) 2001-03-15
ES2273425T3 (es) 2007-05-01
ATE340801T1 (de) 2006-10-15
PL337970A1 (en) 2000-09-11
IS5331A (is) 1999-12-30
DE69836023D1 (de) 2006-11-09
CZ298110B6 (cs) 2007-06-27
AR013157A1 (es) 2000-12-13

Similar Documents

Publication Publication Date Title
TR200000006T2 (tr) Yeni formülasyon.
DE69819811D1 (de) Verbrennungsverfahren mit zweifacher Oxidationsmitteleinfuhr
ATE351896T1 (de) Brennstoffzusammensetzung
ATE228357T1 (de) Nukleotid-analoge zusammensetzung
DK1022334T3 (da) Hidtil ukendte amylaser
IT1296601B1 (it) Cellula fotoelettrica ad amplificazione stabilizzata.
DE69715256D1 (de) Brennkammer
DE69929282D1 (de) Brennkammer
DE69800983D1 (de) Verdickte filmbildende Zusammensetzung
UY34152A (es) ?oxazolidinonas substituidas y su uso?.
DE69822277D1 (de) Lumineszierende Glaskeramik
DE69919764D1 (de) Brennkammer
DE69717050D1 (de) Brennkammer
TR199902516T2 (xx) Kalsilitik bile�imleri.
DE69821065D1 (de) Brennstoffzufuhr
ID23013A (id) Bahan-bahan farmakologi
DE69910106D1 (de) Brennkammer
TR200003587T2 (tr) Nosatiasin antibiyotikleri.
DE69825133D1 (de) Feste Brennstoffzusammensetzung
ID16192A (id) Proses pembuatan asam-asam .alpha., beta-karboksilat organik tak jenuh
DE69804313D1 (de) Filmbildende zusammensetzung
DE59711737D1 (de) Gewölbtes Metall-Keramik-Substrat
DE59901946D1 (de) Brennkammeranordnung
DE59807433D1 (de) Brennkammer
ITTO970975A0 (it) Composizioni organiche.